Single-cell sequencing and machine learning reveal the role of dioxin-interacting genes in HCC prognosis and immune microenvironment.

Journal: Ecotoxicology and environmental safety
Published Date:

Abstract

Dioxins are persistent environmental pollutants that bioaccumulate in the food chain, posing significant risks to human health. Despite their low environmental concentrations, dioxins accumulate in tissues, particularly in top predators and humans, reaching levels far exceeding environmental exposure. Although the carcinogenic potential of dioxins is well recognized, the molecular mechanisms driving hepatocellular carcinoma (HCC) development remain poorly understood. To address this gap, single-cell and bulk transcriptomic analyses, combined with machine learning, identified dioxin-interacting differentially expressed genes (DI-DEGs) associated with immune evasion, metabolic reprogramming, and cell cycle regulation in HCC. A prognostic model based on these DI-DEGs stratified patients into high- and low-risk groups, revealing distinct survival outcomes. High-risk patients exhibited increased cell proliferation and aggressive tumor traits, while low-risk patients showed better metabolic stability and immune surveillance. Drug sensitivity analysis revealed differential responses to chemotherapy agents, suggesting therapeutic implications. In vitro experiments demonstrated that environmentally relevant dioxin concentrations promote HCC cell proliferation and migration. Additionally, molecular docking revealed strong binding between dioxin and DI-DEG proteins, suggesting them as therapeutic targets to mitigate dioxin's harmful effects. These findings underscore the pivotal role of dioxin accumulation in liver cancer progression and provide a foundation for personalized treatment strategies and improved prognostic assessment.

Authors

  • Senyan Wang
    Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, China; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Qi Liu
    National Institute of Traditional Chinese Medicine Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Xiaoyan Sun
    Department of Otorhinolaryngology, Weifang People's Hospital Weifang Shandong, Weifang 261041, Shandong, China.
  • Minghui Hou
    ExxonMobil Asia Pacific Research and Development Company Limited, Shanghai, 200241, P. R. China.
  • Wenjuan Wei
    Scientific and Technical Center for Building (CSTB), Health and Comfort Department, French Indoor Air Quality Observatory (OQAI), University of Paris-Est, Marne la Vallée Cedex 2, France.
  • Hao Song
    Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Jing Xu
    First Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Danyang Lu
    Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, China.
  • Jing Fu
    Shaoxing Second Hospital, 123 Yanan Road, Shaoxing, Zhejiang 312000, PR China.
  • Xiaofang Zhao
    Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, 100069, P. R. China.
  • Hongyang Wang
    State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, PR China.